Can Lower-Risk MDS Achieve High Reward with Hypomethylating Agent Therapy?

Rafael Bejar1

  • 1Moores Cancer Center at UC San Diego Health, La Jolla, CA.

NEJM Evidence
|February 6, 2024
PubMed